Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleYahoo Finance· May 11, 2026

Novo Nordisk Refocuses On GLP‑1 As AI Partner Advances Parkinson’s Bet

“For a company that just reported DKK 96,823 million in Q1 2026 sales and DKK 48,557 million in net income”

Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Cellular Intelligence's AI platform aims to shorten development and manufacturing timelines for the Parkinson's cell therapy, but the program is still early stage and Parkinson's remains a tough indication.
60% confidence
Novo Nordisk is exiting direct cell therapy operations while taking an equity stake in Cellular Intelligence.
60% confidence
By handing global rights for the Phase 1/2 allogeneic cell therapy to Cellular Intelligence and closing its own cell therapy unit, Novo Nordisk avoids the capital intensity and technical risk of building in-house cell therapy and AI capabilities.
60% confidence
For a company that reported DKK 96,823 million in Q1 2026 sales and DKK 48,557 million in net income, the cell therapy divestment appears less like a scale play and more like portfolio pruning alongside the larger GLP-1 franchise.
60% confidence
Novo Nordisk keeps exposure to regenerative medicine through equity, milestones, and potential royalties if the Parkinson's program progresses.
60% confidence
Cellular Intelligence plans to use its AI platform to support development of the Parkinson's therapy.
60% confidence